NanoFCM

21/04/2026

Webinar Alert: Unlocking mRNA-Based Therapeutics with NanoFCM
🗓 Date: April 29, 2026
🕕 Time: 06:30 AM PT / 9:30 AM ET / 3:30 PM CET
🔗 Register Now: https://www.labroots.com/ms/webinar/unlocking-mrna-based-therapeutics-key-data-measurement-nanofcm?campaign=code

Join Khash, Scientist at NanoFCM, for an insightful session on how our NanoAnalyzer technology is revolutionizing LNP characterization in mRNA-based therapeutics!
🔎 In this webinar, you will:
💡 Understand the analytical challenges of characterizing heterogeneous LNP formulations.
💡 Compare conventional methods (DLS, RiboGreen) with single-particle approaches.
💡 Discover how NanoFCM’s NanoAnalyzer provides rapid, accurate, and cost-effective insights into LNP size, concentration, and cargo distribution.

With NanoFCM, you get all the key data in one measurement, simplifying your workflows and providing deeper insights into your LNPs.

Over the recent years, LNPs have paved new possibilities in the world of nanomedicine. From early stage research to clinical manufacturing, having accurate and comprehensive characterisation

02/04/2026

Unlocking New Insights into Ligand Density with NanoAnalyzer: A Game Changer in tLNP development
💥We're thrilled to see NanoFCM featured in Nano Letters, where it demonstrates unprecedented sensitivity in measuring ligand density at the single-nanoparticle level. In the recent study by Nitto Denko, the NanoAnalyzer from NanoFCM once again delivered exceptional sensitivity—offering a comprehensive solution for precise ligand quantification.
🔬 This breakthrough represents a major advancement for targeted LNPs, enabling researchers to quantify ligand availability and receptor interactions with previously unattainable precision—paving the way for progress in cancer immunotherapy and drug development.
Read the full study to explore how NanoFCM is advancing the understanding of ligand density:[DOI:10.1021/acs.nanolett.5c06525].
✉️Contact Us for More Information About Ligand Density Analysis！
https://www.nanofcm.com/

| | | | | | |

02/04/2026

Five days countdown! Meet us in Boston at the LNP Formulation and Process Development Summit!
💡 If you're attending the event, don’t miss Jimmy’s talk: Single LNP Characterization for Formulation & Process Development: Understanding Empty particles, Payload Distribution & Targeting Molecule Display.
We look forward diving deep into cutting-edge methods for understanding lipid nanoparticle (LNP) Characterization at the single-nanoparticle level with you at Booth 11.

28/10/2025

🔬 Underfilled or even overfilled LNPs? Does it matter?
Encapsulation efficiency (EE%) isn’t just a cost metric—it drives potency, safety, and reproducibility.

Underfilling (many empties, low mRNA copies/LNP)
→ Need more starting mRNA to see in vivo biological effect → higher lipid for same biology can cause tolerability risk + variability.

Overfilling (few LNPs with high mRNA copies)
→ Heterogeneous dose per cell, possible endosomal-escape bottlenecks, aggregation risk.

A fast and practical screen with single particle analytics:
→ NanoFCM helps you analyze critical parameters: EE%, % empty/full LNPs+ mRNA copies/LNP
→ Gate to advance: EE ≥ 80–90%, % full ≥ 60–70%, median copies/LNP in target band, tight PDI
→ Re-check after N/P tweaks, buffer swaps, and a freeze–thaw

Formulation optimization:
N/P ratio, ionizable lipid pKa, helper lipids, solvent, T/MFR
Rapid EE readouts help rank hits and map structure, process to performance fast.

🌟🌟Why early single particle analytics for EE% + filled particle ratios pays off in the long run🌟🌟
Safety & tolerability: Low EE% → more free mRNA or more lipid per effective dose
Consistency & translatability: Flags batch noise before costly PD/PK
Stability & developability: EE% trends under stress/aging predict potency drift and guide excipients

If you’re running LNP screens, single-particle analytical data is paramount —you’ll move faster with fewer surprises.

23/10/2025

Encapsulation efficiency : The percentage of total mRNA that is packaged inside LNPs is a key quality attribute.
🔬Conventional RiboGreen assays report this bulk EE% does not reveal how that RNA is distributed across particles.
🔬You can have EE% ≈100% yet still have many empty LNPs if the cargo is concentrated in a subset of particles.

How single-particle analysis with nano flow cytometer is better :
🔬Single particle analysis detects co-occurring signals from an mRNA label and a lipid dye.
🔬Controls with two lipid dyes showed ~100% co-occurrence, validating the method.
🔬For each LNP, this method compute both the fraction of empty/full LNPs and the payload heterogeneity (mRNA copies per LNP)
🔬By varying the ionizable-lipid-to-mRNA charge ratio (N/P), the best overall loading is discovered (more full particles and higher per-particle mRNA)
🌟Formulation parameters shape not only how many LNPs are loaded but also how much each one carries.
🌟Unlike bulk assays, single particle analysis with nano flow provides particle-resolved metrics that are valuable for formulation development and QC.

19/09/2025

🚀The In Vivo CAR-T Race is here: Big Pharma Scrambles to Acquire In Vivo CAR-T Leaders and Secure the Future of Cell Therapy

🔬 Join Joseph Brealey to find out more about the game-changing in vivo CAR reprogramming approach and how multiple analytics are consolidated into a single workflow, saving time and cost without compromising data quality for your CAR therapy research and development.

🗓️ LIVE Broadcast: Thursday, Oct. 2 - 8:00 PT, 11:00 ET, 17:00 CET

Register here 👉 https://www.nanofcm.com/category/webinars/

26/08/2025

🔬 From noise to real signal: making low antigen expression visible.

Native virions typically carry very few copies of surface antigens, so their fluorescence often falls at or near background levels on most cytometers.
📉 Example (HIV–CD38 staining): transformed T-cell line preparations yield ~170 PE-MESF; primary PBMC-derived virions yield ~74 PE-MESF. Many events overlap with or fall into the negative population.
🧪 Whether a particle is called “positive” depends on how bright its signal is compared to the background—not on setting an arbitrary gate.

Here’s how you can improve signal-to-noise and enable low-copy detection:
1. Calibrate to MESF and report LOD/LOQ.
2. Use strong controls: buffer blank, unstained virus, isotype/FMO, dye-only.
3. Maximize photons per particle: use brighter fluorophores, optimize antibody labelling and stoichiometry, and incorporate amplification where compatible.
4. Minimize background: use phenol red–free buffers, clean up serum/dye, choose proper filter sets, and optimize threshold.
5. Keep gating honest: use size/SSC gating for virions, apply coincidence rejection, and maintain consistent compensation.

⚠ Note: MESF ≠ copy number. MESF reports fluorophore equivalents; converting to molecules requires assumptions (e.g., F/P ratio, valency, epitope accessibility).

22/08/2025

🔬Functional titer assays (plaque assay, TCID₅₀, focus-forming assays) measure infectious particles, not just physical ones.

🔬Flow Virometry (FV) can measure how many viral particles are present, but it cannot directly determine how many are infectious. By extending FV to quantify key viral attributes such as genome content and essential proteins, a Functional Proxy Titer (FPT) can be derived.

🔬FPT serves as a rapid indicator that tracks with infectivity (transduction unit count), giving you a reliable estimate of infectious potential in under an hour when traditional TU assays are too slow

🌟 Functional titers remain the regulatory gold standard for vaccines and therapeutic viral vectors. However, FV can serve as a rapid ‘first look’ when time is critical. By providing quick QC on particle concentration, size, integrity, and subpopulations, FV is increasingly recognized as a powerful complementary assay for functional titer measurements.

21/08/2025

Partlow et al. used quantitative flow virometry (FV) to demonstrate that influenza A virus can rapidly shift its particle output from spherical to filamentous forms as a survival strategy.

This high-impact study has major implications for understanding viral pathogenesis, transmission, and vaccine design, as it revealed real-time, population-level changes in virion morphology that classical bulk assays could never capture at scale.

Influenza virologists typically rely on:
🧪Hemagglutination assay (HA assay) → gives only bulk “activity” readout, not particle count.
🧪Plaque assays → measure infectivity but are slow and labor intensive.
🧪Electron microscopy (EM) → beautiful images but extremely low throughput, not quantitative.
🧪DLS/NTA → bulk or semi-bulk methods that give size averages but cannot resolve particle heterogeneity.
👉 None of these methods can tell researchers what's happening on individual virions, or detect subpopulations within a viral prep.

🌟 The FV Advantage (Single-Particle Analysis)
🔬detection and analysis of viruses down to sizes of approximately 27–100 nm and provides absolute particle concentrations (particles/mL)
🔬Fluorescent antibodies can be employed to label viral surface antigens and quantify them (e.g. Hemagglutinin or Neuraminidase)
🔬Quantifies each virion separately → reveals heterogeneity (e.g. spherical vs. filamentous particles, variable protein incorporation).
🔬High throughput → measures tens of thousands of particles, statistically robust.
🔬Multiparametric → can combine size/shape info with fluorescence immunophenotyping.
🔬Comparable across labs → with fluorescence/scatter calibration (MESF, Rosetta, etc.).
🔬FV could enable real-time vaccine QC, measuring particle size and concentration directly in prep batches.

20/08/2025

NanoFCM is helping to solve the long-standing problem of distinguishing viruses from host-derived nanoparticles mixture.

Viruses and extracellular vesicles often overlap in size and density, making it hard to study one without contaminating presence of the other. A new NanoFCM-based method uses fluorescent DNA/RNA stains to identify virus particles by their genome content. A 2025 study demonstrated by Vladimir et al. showed staining EV-virus mixed sample allowed clear discrimination of HCMV virions (DNA-positive and higher scatter) from EVs (DNA-negative, lower scatter) on single-particle plots. This approach enabled simultaneous quantification of viruses and EVs produced in the same culture.

The authors then leveraged NanoFCM to guide an improved purification protocol, achieving cleaner separation of exosomes from virions. This is a novel application that combines virology and EV research, giving virologists a tool to rigorously assess how much EV “contamination” is in virus preps and vice versa.

14/08/2025

Flow virometry enables the detection and analysis of viruses down to sizes of approximately 27–100 nm. It uses light scattering (side scatter) to estimate particle size distribution and provides absolute particle concentrations (particles/mL) by referencing calibration beads.

Fluorescent antibodies can be employed to label viral surface antigens (e.g., spike proteins, envelope proteins). Using fluorescence calibration beads, the method can quantify protein density per particle. Internal markers can also be detected if the viral membrane is permeabilized. For small particles such as viruses, both fluorescence and light scatter calibration have been demonstrated such as using QuantiBRITE MESF beads for fluorescence calibration, and Rosetta or FCMPass beads for scatter calibration. These calibrations correct for instrument-to-instrument variability and enable true quantitative comparisons across different flow cytometers and over time.

Notably, Burnie et al. (2020) applied calibrated FV to quantify human integrin α4β7, CD14, and PSGL-1 on HIV-1 pseudoviruses, reporting results in standardized units (PE MESF/nm²). Maltseva et al. (2022) performed similar calibrated flow virometery analyses on MLV particles, further supporting the method’s reliability for quantifying viral surface proteins.